ABSTRACT
Metabolic syndrome (MetS) is a complex metabolic disorder with a global prevalence of 20-25%. Early identification and intervention would help minimize the global burden on healthcare systems. Here, we measured over 400 proteins from ∼20,000 proteomes using data-independent acquisition mass spectrometry for 7890 serum samples from a longitudinal cohort of 3840 participants with two follow-up time points over ten years. We then built a machine learning model for predicting the risk of developing MetS within ten years. Our model, composed of 11 proteins and the age of the individuals, achieved an area under the curve of 0.784 in the discovery cohort (n=855) and 0.774 in the validation cohort (n=242). Using linear mixed models, we found that apolipoproteins, immune-related proteins, and coagulation-related proteins best correlated with MetS development. This population-scale proteomics study broadens our understanding of MetS, and may guide the development of prevention and targeted therapies for MetS.
Competing Interest Statement
Y.Z. and T.G. are shareholders of Westlake Omics Inc. B.W., W.G., and N.X. are employees of Westlake Omics Inc. The other authors declare no competing interests.
Clinical Trial
NCT03179657
Funding Statement
This work is supported by grants from the National Key R&D Program of China (No. 2021YFA1301602, 2021YFA1301603, and 2021YFA1301601), the National Natural Science Foundation of China (No. 82073546, 81773416, and 82103826) and Zhejiang Provincial Natural Science Foundation of China (LQ21H260002). We thank Westlake University Supercomputer Center for assistance in data generation and storage. We thank all study participants of the Guangzhou Nutrition and Health Study and all other team members involved in the cohort study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Medical Ethical Committee of Westlake University
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the raw data will be publicly released after publication. The phenotype data can be requested by email from the corresponding author (Y.C).
